PEGylation: Posttranslational bioengineering of protein biotherapeutics

Drug Discovery Today: Technologies

Volumn 5, Issue 2-3, 2008, Pages

  Veronese, Francesco M ^a   Pasut, Gianfranco ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; CERTOLIZUMAB PEGOL; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HYBRID PROTEIN; LIPOSOME; MACROGOL; NANOPARTICLE; NEW DRUG; PEGADEMASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGVISOMANT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACYLATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG HALF LIFE; DRUG PURIFICATION; DRUG SAFETY; DRUG SYNTHESIS; FEASIBILITY STUDY; HYDROGEL; IMMUNOGENICITY; IN VIVO STUDY; KIDNEY CLEARANCE; PATENT; PROTEIN AGGREGATION; PROTEIN ENGINEERING; PROTEIN GLYCOSYLATION; REVIEW;

EID: 71849084612     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2009.02.002     Document Type: Review

References (44)

1. Leader B., et al. Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 7 (2008) 21-39
2. In: Harris J.M., and Veronese F.M. (Eds). Peptide and protein PEGylation III: advances in chemistry and clinical applications. Adv. Drug Del. Rev. 60 (2008) 1-88
3. Pasut G., and Veronese F.M. Polymer-drug conjugation, recent achievements and general strategies. Prog. Polym. Sci. 32 (2007) 933-961
4. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6 (2006) 688-701
5. Abuchowski A., et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252 (1977) 3582-3586
6. Abuchowski A., et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252 (1977) 3578-3781
7. Greco F., and Vicent M.J. Polymer-drug conjugates: current status and future trends. Front Biosci. 13 (2008) 2744-2756
8. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2 (2003) 347-360
9. Petrak K., and Goddard P. Transport of macromolecules across the capillary walls. Adv. Drug Del. Rev. 3 (1989) 191-214
10. Yamaoka, et al. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83 (1994) 601-606
11. Yamaoka T., et al. Fate of water-soluble administered via different routes. J. Pharm. Sci. 84 (1995) 349-354
12. Kawai F. Microbial degradations of polyethers. Appl. Microbiol. Biotechnol. 58 (2002) 30-38
13. Beranova M., et al. Effect of cytochrome P-450 inhibition and stimulation on intensity of polyethylene degradation in microsomial fraction of mouse and rat livers. Biomaterials 11 (1990) 521-524
14. Roseng L., et al. Uptake, intracellular transport, and degradation of polyethylene glycol-modified asialofetuin in hepatocytes. J. Biol. Chem. 267 (1992) 22987-22993
15. Bendele A., et al. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol. Sci. 42 (1997) 152-157
16. Conover, et al. Physiological effect of polyethylene glycol conjugation on stroma-free bovine hemoglobin in the conscious Dog after partial exchange transfusion. Artif. Organs 21 (1997) 369-378
17. Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotech. Ann. Rev. 14 (2008) 191-202
18. Raso S.W., et al. Aggregation of granulocyte-colony stimulating factor in vitro involves a conformationally altered monomeric state. Protein Sci. 14 (2005) 2246-2257
19. Rajan S.R., et al. Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study. Protein Sci. 15 (2006) 1063-1075
20. Veronese F.M., et al. Site-specific pegylation of G-CSF by reversible denaturation. Bioconjug. Chem. 18 (2007) 1824-1830
21. Ganson N.J., et al. Control of hyperuricemia in subjects with refractory gout, and induction of antibody agaist poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res. Ther. 8 (2006) R12
22. Armstrong J.K., et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110 (2007) 103-111
23. Richter A.W., and Akerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int. Arch. Allergy Appl. Immunol. 70 (1983) 124-131
24. Cheng T.L., et al. Monoclonal antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles. Bioconjug. Chem. 16 (2005) 1225-1231
25. Balan S., et al. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge. Biocon. Chem. 18 (2007) 61-76
26. DeFrees S., et al. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology 16 (2006) 833-843
27. Sato H. Enzymatic procedure for site-specific pegylation of proteins. Adv. Drug Deliv. Rev. 54 (2002) 487-504
28. Fontana A., et al. Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Adv. Drug Deliv. Rev. 60 (2008) 13-28
29. Mero A., et al. Transglutaminase-mediated PEGylation of proteins: direct identification of the sites of protein modification by mass spectrometry using a novel monodisperse PEG. Biocon. Chem. 20 (2009) 384-389
30. Wang Y.S., et al. Structural and biological characterisation of pegylated recombinant interferon α-2b and its therapeutic implications. Adv. Drug Deliv. Rev. 54 (2002) 547-570
31. Molek J.R., and Zydney A.L. Ultrafiltration characteristics of pegylated proteins. Biotechnol. Bioeng. 95 (2006) 474-482
32. ®) for the treatment of hepatitis C. Adv. Drug Deliv. Rev. 54 (2002) 571-586
33. Wong S.S. Reactive groups of proteins and their modifying agents. Chemistry of Protein Conjugation and Cross-linking (1991), CRC Press p. 13
34. Nesbitt A., et al. Certolizumab pegol: a PEGylated anti-tumour necrosys factor alpha biological agent. In: Veronese F.M., and Bossard M. (Eds). PEGylated Protein Drugs: Basic Science and Clinical Application (2009), Birkhauser Verlag Press (SW)
35. Ng E.W.M., et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5 (2006) 123-132
36. Pasut G., et al. Anti-cancer PEG-enzymes: 30 years old, but still a current approach. Adv. Drug Deliv. Rev. 60 (2008) 69-78
37. Pinto Reis C., et al. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine 2 (2006) 53-65
38. Almeida A.J., and Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 59 (2007) 478-490
39. Martins S., et al. Lipid-based colloidal carriers for peptide and protein delivery - liposomes versus lipid nanoparticles. Int. J. Nanomed. 2 (2007) 595-607
40. Tessmar J.K., and Göpferich A.M. Matrices and scaffolds for protein delivery in tissue engineering. Adv. Drug Deliv. Rev. 59 (2007) 274-291
41. Jazayeri J.A., and Carroll G.J. Fc-based cytokines: prospects for engineering superior therapeutics. BioDrugs 22 (2008) 11-26
42. Schulte S. Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa. Thromb. Res. 122 Suppl. 4 (2008) S14-S19
43. Elliott S., et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat. Biotechnol. 21 (2003) 414-421
44. Jones M.C., and Patel M. Insulin detemir: a long-acting insulin product. Am. J. Health Syst. Pharm. 63 (2006) 2466-2472